Patents for A61P 35 - Antineoplastic agents (221,099)
10/2004
10/19/2004US6806063 Protein conjugate for use in the treatment of blood disorder
10/19/2004US6805863 Comprises antibodies/proteins providing inhibition of prothrombinase; treatment and prevention of bacterial and viral infections, allograft/xenograft rejection, glomerulo-nephritis, cancer, gastrointestinal diseases, and fetal loss
10/19/2004US6805861 Administering therapeutically effective amount of cytotoxic t lymphocytes which have different hla class i complex (or equivalent) than cells to be killed, and specifically recognize peptide portion of antigen presented on cell surface
10/19/2004CA2323096C Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
10/19/2004CA2238574C Targeted cytotoxic anthracycline analogs
10/14/2004WO2004087921A1 Human solid cancer antigen peptides, polynucleotides encoding the same and utilization thererof
10/14/2004WO2004087917A1 Thioredoxin modification
10/14/2004WO2004087763A1 Modified antibody against cd22 and utilization thereof
10/14/2004WO2004087762A1 Antibodies inhibiting tansportation activity of peptide transporter
10/14/2004WO2004087758A2 Il 13 receptor alpha 2 antibody and methods of use
10/14/2004WO2004087756A2 Antibodies against insulin-like growth factor i receptor and uses thereof
10/14/2004WO2004087734A2 Stq-peptides
10/14/2004WO2004087717A1 Non-cross-linking pyrrolo[2,1-c][1,4]benzodiazepines as potential antitumour agents and process thereof
10/14/2004WO2004087716A1 Pyrrolo[(2,1-c)(1,4) benzodiazepines dimers as antitumour agents and process thereof
10/14/2004WO2004087713A1 Salts of tricyclic inhibitors of poly(adp-ribose) polymerases
10/14/2004WO2004087712A1 NEW PYRIMIDINE LINKED PYRROLO[2,1-c][1,4]BENZODIAZEPINES AS POTENTIAL ANTITUMOUR AGENTS
10/14/2004WO2004087711A1 Pyrene-linked pyrrolo (2,1-c) (1,4) benzodiazepine derivatives useful as anticancer agents
10/14/2004WO2004087707A1 Pyrazolopyrimidine compounds and their use in medicine
10/14/2004WO2004087699A2 Thiazoles useful as inhibitors of protein kinases
10/14/2004WO2004087698A2 Thiazoles useful as inhibitors of protein kinases
10/14/2004WO2004087693A1 Oxime derivatives and their use as pharmaceutically active agents
10/14/2004WO2004087679A1 2, 4, 6-trisubstituted pyrimidine derivatives useful for the treatment of neoplastic and autoimmune diseases
10/14/2004WO2004087673A2 Migrastatin analogs and uses thereof
10/14/2004WO2004087672A1 Migrastatin analog compositions and uses thereof
10/14/2004WO2004087652A2 Imidazotriazine compounds
10/14/2004WO2004087646A2 Pyrrolidino-1,2-dicarboxy-1-(phenylamide)-2-(4-(3-oxo-morpholino-4-yl)-phenylamide) derivatives and related compounds for use as inhibitors of coagulation factor xa in the treatment of thrombo-embolic diseases
10/14/2004WO2004087641A1 Hydrazone derivative
10/14/2004WO2004087208A1 Thermotherapeutic for malignant tumor comprising heat shock protein and fine magnetic particles
10/14/2004WO2004087207A2 Method for inducing apoptosis and aneuploidy regression in cancer cells
10/14/2004WO2004087205A1 Cytotoxicity mediation of cells evidencing surface expression of gp96 or precursors thereof
10/14/2004WO2004087195A2 Therapeutic use of modulators of notch and/or kruppel-like factors
10/14/2004WO2004087186A1 Composition and method for supporting cancer treatments
10/14/2004WO2004087182A1 Active ingredient combinations of plant oils containing $g(v)3-fatty acids and plant extracts containing isoprenoids and the use thereof
10/14/2004WO2004087165A1 Therapeutic agent for prostatic hypertrophy
10/14/2004WO2004087152A1 Dosage forms comprising ag013736
10/14/2004WO2004087128A1 Methyl-β-orcinolcarboxylate from lichen (everniastrum cirrhatum) for use for the treatment of fungal infections and cancer
10/14/2004WO2004087123A1 Prevention and treatment of breast cancer with 4-hydroxy tamoxifen
10/14/2004WO2004087121A2 Water soluble formulations of digitalis glycosides for treating cell-proliferative and other diseases
10/14/2004WO2004087109A1 Medicinal oral preparations for colon delivery, medicinal oral preparations for treating colon cancer and medicinal oral preparations for treating colitis
10/14/2004WO2004087075A2 Compositions and methods for treating cancer
10/14/2004WO2004071397A3 Combination therapy of zd6474 with 5-fu or/and cpt-11
10/14/2004WO2004067550A3 Novel use of mifepristone and derivatives thereof as hedgehog protein signalling pathway modulators and applications of same
10/14/2004WO2004052315A3 Tyrosine kinase inhibitors
10/14/2004WO2004044229A3 DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH HUMAN PHOSPHODIESTERASE 7A2 (PDE7a2)
10/14/2004WO2004042402A3 Diagnostics and therapeutics for diseases associated with human mas-related gene x1 (mrgx1)
10/14/2004WO2004032840A3 Compounds, compositions, and methods
10/14/2004WO2004031775A3 Method for treating or preventing metastasis of colorectal cancers
10/14/2004WO2004031774A3 Method for treating or preventing metastasis of colorectal cancers
10/14/2004WO2004029046A3 Novel raloxifene acid addition salts and/or solvates thereof, improved method for purification of said raloxifene acid addition salts and/or solvates thereof and pharmaceutical compositions comprising these
10/14/2004WO2004024063A3 Compositions and methods for the diagnosis and treatment of tumor
10/14/2004WO2004021010A3 Method of diagnosing colon and gastric cancers
10/14/2004WO2004016769A3 Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof
10/14/2004WO2004000781A3 Nitrooxyderivatives of cyclooxygenase-2 inhibitors
10/14/2004WO2003031475A8 Antibodies against kdr, their production and uses
10/14/2004US20040205832 Transgenically produced decorin
10/14/2004US20040204673 Modular infusion device and method
10/14/2004US20040204617 Solvent extraction to remove free radical of p-benzoquinone (p-benzosemiquinone) from cigarette; purification, crystallization and quantitative analysis
10/14/2004US20040204599 an end-terminal group, which is isopropyl, sec.-butyl, or tert.-butyl group; a leading group; and a long-chain aliphatic, non-cyclic, saturated or unsaturated, hydrocarbon group that links end-terminal group and leading group; for cancer therapy, prevention, and immune boosting and inflammation functions
10/14/2004US20040204596 preventing or treating degradation of collagen, degradation of collagen by bacterial collagenases during a bacterial infection, regeneration of skin and ligaments, tumoral invasion and degenerative diseases having fibrinoid degeneration of collagen
10/14/2004US20040204590 Ep4 receptor agonist, compositions and methods thereof
10/14/2004US20040204588 aryl hydrocarbon; oxidation of 4,5-dihydro-1,3-azoles to fully unsaturated ring; heterocyclic ketones
10/14/2004US20040204586 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
10/14/2004US20040204582 Substituted sulfonamides and ureas useful for inhibiting kinase activity
10/14/2004US20040204568 Comprises nucleotide sequences coding cell adhesion molecules for use in the diagnosis, prevention and treatment of autoimmune and cell proliferative disorders
10/14/2004US20040204565 Use of multivalent chimeric peptide-loaded, MHC/IG molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
10/14/2004US20040204494 Having anticancer, anti-proliferous and anti-inflammatory effects and immunosuppressive and muscle relaxing functions
10/14/2004US20040204482 provides a defined blood concentration profile having no rapid initial rise in blood plasma concentration of the good soluble active substance when administered; (R)-3-N,N-dicyclobutylamino-8-fluoro-3,4-dihydro-2H-1-benzopyran-5-carboxamide; nervous system, gastrointestinal, heart disorders, Alzheimer's
10/14/2004US20040204481 Activation of natural killer cells by adenosine A3 receptor agonists
10/14/2004US20040204480 Anti-cancer combinations
10/14/2004US20040204477 For use as antiproliferative agents
10/14/2004US20040204465 Crystal form of N-(4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide
10/14/2004US20040204464 Isoxazoline compounds having MIF antagonist activity
10/14/2004US20040204456 Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
10/14/2004US20040204452 to decompose peroxynitrite anion into harmless nitrate or nitrite endproducts which prevents the free radical-mediated cell damage; cytoprotective; Alzheimer's disease; 3,5-dimethylisoxazole-4-sulfonic acid 4-pyrrolidin-1-ylphenylamide
10/14/2004US20040204449 New isoquinoline compounds
10/14/2004US20040204438 such as N-[4-(4-amino-1H-imidazol[4,5-c]quinolin-1-yl)butyl]-5-(dimethylamino)-naphthalenesulfonamide; for induction of biosynthesis of cytokines; immunomodulators; antineoplastic agents
10/14/2004US20040204437 Substituted arylamine derivatives and methods of use
10/14/2004US20040204436 Imidazonaphthyridines
10/14/2004US20040204435 Alternating treatment with topoisomerase I and topoisomerase II inhibitors
10/14/2004US20040204427 Inhibitors of both KDR an FGFR kinases and are selective against LCK; for therapy of solid tumors, in particular breast, colon, lung and prostate tumors.
10/14/2004US20040204419 For therapy of cancer
10/14/2004US20040204417 For therapy of cancer
10/14/2004US20040204408 Piperidinyl-morpholinyl derivatives as modulators of chemokine receptor activity
10/14/2004US20040204395 Water-soluble drugs and methods for their production
10/14/2004US20040204390 Pharmaceutical combination comprising an anti-androgen and an oestrogen receptor beta agonist
10/14/2004US20040204368 Oxadiazole derivative compounds and drugs containing these compounds as the active ingredient
10/14/2004US20040204364 Peptides for activation and inhibition of deltaPKC
10/14/2004US20040204361 Kdel receptor inhibitors
10/14/2004US20040204345 Using recombinant zinc finger proteins; use in human therapeutic applications such as cancer therapy and altering plant phenotypes, including disease resistance, fruit ripening
10/14/2004US20040203118 Polynucleotides and polypeptides of the IFNalpha-14 gene
10/14/2004US20040203111 UDP-N-acetylglucosamine: galactose-B1,3-N-acetylgalactosamine-a-R/ (GlcNAc to GalNAc) B1-6 N- acetylglucosaminyltransferase, C2GnT3
10/14/2004US20040203105 for drug screening emzyme inhibitors using genetically engineered animal models; for anticancer agents
10/14/2004US20040203104 for drug screening enzyme inhibitors; genetic engineering; comprising subjecting the sample to a polymerase chain reaction, a northern hybridization assay or an in situ hybridization assay
10/14/2004US20040203098 Compounds and methods for modulating activation of NF-kappaB
10/14/2004US20040203097 Kinases and phosphatases
10/14/2004US20040203092 UDP-N-acetylglucosamine:galactose-beta1,3-N-acetylgalactosamine-alpha-R/ (GlcNAc to GalNAc) beta1-6 N-acetylglucosaminyltransferase, C2GnT3
10/14/2004US20040203051 Nucleotide sequences coding two or more tumor associated antigens for use in identify modulators of major histocompatibility complex; preventing infections
10/14/2004US20040203039 Attenuated salmonella SP12 mutants as antigen carriers
10/14/2004US20040203014 Neurotransmisson-associated proteins
10/14/2004US20040203003 comprising isolating messenger RNA and performing reverse transcription polymerase chain reaction (PCR) and assessing the concentrations of the resulting amplicons; genetic engineering